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Medical practitioners in South Africa are increasingly 
confronted with requests to treat patients with opioid use 
disorders. Many do not possess the required knowledge and 
skills to deal with these patients effectively. This overview of 
the medical treatment of opioid dependence was compiled 
by an elected working group of doctors working in the field 
of substance dependence. Recommendations are based on 
current best practice derived from scientific evidence and 
consensus of the working group, but should never replace 
individual clinical judgement. 
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Extent of the problem
Heroin is the main illicit opioid of abuse, with an increasing 
trend in South Africa. Between 11% and 23% of all patients 
who presented for substance rehabilitation in the second half 
of 2006 stated that heroin was their primary or secondary drug 
of choice.1 
The use of heroin in combination with other drugs has also 
become popular. It includes ‘nyaope’ and ‘pinch’ (mixture 
of cheap heroin and cannabis) and ‘sugars’ (mixture of low-
quality heroin and cocaine, mixed with cannabis). Heroin is 
mostly smoked in South Africa; the incidence of intravenous 
use varies geographically and is as high as 42% in Gauteng.1 
Owing to the purity of available heroin in many parts of South 
Africa, smoking and sniffing it can give a ‘high’ that is equal to 
that of injection use. 
Between 5% and 8% of treatment seekers in addiction 
treatment facilities have problems with over-the-counter or 
prescription medication abuse as their primary or secondary 
drug of choice; these medications include codeine- and 
dextropropoxyphene-containing analgesics and cough 
mixtures. This makes up a significant group of opioid abusers 
with concerning morbidity, in part because of the toxicity of 
other ingredients, including paracetamol.1 
What is opioid dependence? 
Opioid dependence is a chronic relapsing disease that develops 
from repeated self-administration of opioids, including 
heroin, over-the-counter and prescription opioids. Genetic and 
environmental factors contribute to the development of this 
disease.2 Repeated exposure to opioids can cause enduring 
structural and functional brain changes that are associated 
with distinctive behavioural patterns including compulsive 
substance seeking and repeated use despite horrendous 
consequences.
‘Opioid’ refers to all substances, natural and synthetic (such 
as pethidine) that act on the mu-opioid receptors in the brain. 
‘Opiate’ refers to derivatives of opium (such as morphine, 
heroin or codeine). Routine drug screens test positive only for 
opiates and special testing is required for synthetic opioids.
Opioid dependence is associated with substantial morbidity 
and mortality. Heroin dependence has an annual mortality rate 
of about 1 - 2% and frequently requires long-term treatment. 
It is, however, encouraging that the proportion of clients 
who sustain abstinence increases with time, and the addicted 
proportion declines. In a British cohort of 86 heroin addicts 
followed up for 33 years after first contact, 42% were abstinent 
from all opioids and had been for at least 10 years; 22% had 
died, mostly with substance-related causes of death; 10% were 
on methadone; and 8% could not be located.3  
Abuse v. dependence 
Opioid abuse and dependence require different interventions. 
Abuse implies that someone persistently or sporadically uses 
substances in a manner that causes negative consequences. The 
Diagnostic and Statistical Manual of Mental Disorders, 4th revision 
(DSM-IV), defines it as a maladaptive pattern of substance 
use that leads to impairment or distress manifesting by any of 
the following: failing to fulfil important obligations at work, 
school or home; using substances in a manner that is physically 
hazardous; or having legal, social or interpersonal problems 
due to or exacerbated by the substance. 
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Dependence draws on the physical and psycho-behavioural 
aspects of addiction and is used by the International Statistical 
Classification of Diseases and Related Health Problems, 10th edition 
(ICD-10) and DSM-IV classification systems. Three symptom/
sign domains are recognised:
•    Physical adaptation of the body to the substance (tolerance; 
withdrawal)
•    Loss of control over taking the substance (strong desire 
or sense of compulsion to take the drug; difficulties 
in controlling substance-taking behaviour; desire or 
unsuccessful efforts to cut down or control use), and
•    Salience (great deal of time spent obtaining, using the 
drug or recovering from its effects; progressive neglect 
of alternative pleasures, interests, or important activities; 
continued use despite clear evidence of its harm). 
Abuse is generally managed by using a psycho-educational 
approach, e.g. brief interventions,4 or motivational 
interviewing.5 This article deals with the medical management 
of opioid dependence.
Medical model for the treatment of 
opioid dependence
The aim of treatment for opioid dependence is total abstinence 
from all opioids. In clinical practice, the short-term success rate 
for total abstinence is low, even following inpatient treatment. 
In a 3-month follow-up of 242 opioid-dependent patients 
in residential treatment in the National Treatment Outcome 
Research Study, 34% of the patients relapsed to heroin use 
within 3 days and 60% after 90 days.6
Total abstinence does, however, remain an achievable goal for 
some patients. In 149 patients, following a 6-week residential 
programme followed by aftercare, a total abstinent rate of 
23% after 2 - 3 years was found. Abstinence was significantly 
associated with programme completion and aftercare 
attendance.7 Over time, however, most users eventually 
achieve remission.8 Trends in treating opioid dependence have 
moved from only focusing on total opioid abstinence towards 
including strategies aimed at harm reduction (keeping patients 
alive until they eventually go into remission) and abstinence 
from illicit opioids. This may involve the use of long-term 
oral substitute opioids until the addict is ready to change 
behaviour and maintain sobriety. The two opioids used for this 
substitution therapy are methadone and buprenorphine.
The medical management of opioid dependence can thus be 
conceptualised as involving two potential options:
•   Achieving total abstinence rapidly using standard rapid 
detoxification procedures (withdrawal over 7 - 21 days), 
followed by relapse prevention strategies.
•   Transferring the addict from abused opioids onto an 
individualised dose of substitution opioid (thus markedly 
reducing or preventing illicit drug use, allowing patients 
to stabilise their lifestyle), and slowly detoxifying them 
when they are ready. This shift towards harm reduction 
is not widely accepted in South Africa as there is limited 
infrastructure and no legislation to accommodate opioid 
substitution therapy. It is important that South Africa 
develops the capacity to provide substitution prescription in 
a safe and controlled manner. 
Rapid detoxification from all opioids and relapse 
prevention
Assisting opioid-dependent individuals to achieve the goal of 
abstinence from all opioids rapidly involves:
•   Identification and motivation
•   Detoxification
•    Management of co-morbid medical and mental health 
problems
•    Relapse prevention.
Identification and motivation
The problems of opioid-dependent individuals evoke shame, 
denial and defensiveness in the addict, and negative responses 
in health care workers. Social workers, educators, workers in 
the legal and judicial system, health care workers, and other 
persons involved with these individuals should be educated 
to recognise opioid use disorders early. Health care workers 
need to learn skills in dealing with resistance and motivating 
opioid abusers to engage in treatment services (e.g. brief 
interventions,4 motivational interviewing5) and should be 
familiar with treatment resources in their area.
Article 21/22 of the Prevention and Treatment of Substance 
Dependency Act (1992) and the draft copies of the revised 
version of this Bill, provide for the compulsory treatment  
(‘committal’) of clients who refuse treatment for substance 
dependence and who cause harm to themselves or their 
families. 
Management of co-morbid medical and mental health 
problems
Heroin dependence is associated with a high incidence of 
co-morbid medical and mental health complications, which 
require separate identification and treatment. Fatal overdose 
is tragic and heroin is the drug most implicated in fatal 
accidental poisonings in addicts. Medical complications may 
arise from non-sterile injecting practices or needle sharing, and 
include skin or systemic infections, HIV or hepatitis B or C 
transmission, and complications because of adulterants, which 
may include talcum pneumonitis and renal complications.  
Common psychiatric problems include depression, protracted 
anhedonia (even with long-term abstinence) and personality 
disorders. Psychosis is rare but may arise from poly-substance 
abuse.
April 2008, Vol. 98, No. 4  SAMJ
SAMJ FORUM
Detoxification
Detoxification, the first step of treatment, allows the addict to 
engage in the most important step of treatment, namely relapse 
prevention. It involves a graded and controlled reduction 
in tolerance to opioids, minimising unpleasant withdrawal 
symptoms. Two medication groups are used, often in 
conjunction: opioid substitution and symptomatic medication.
Substitution detoxification involves the use of either a full or 
partial opioid agonist, which is prescribed at an individualised 
dose that alleviates withdrawal symptoms without causing 
intoxication.  It is then gradually reduced, usually over a period 
of 1 - 3 weeks, allowing the level of tolerance to normalise 
in a manner that is tolerable for the addict. It is important to 
ensure that patients are in withdrawal (objective rating scales 
may be useful, e.g. Clincal Opioid Withdrawal Scale (COWS)) 
before administering substitution opioids in order to prevent 
accidental overdose (full agonists) or precipitate withdrawal 
(partial agonists). 
Symptomatic medications alleviate some of the withdrawal 
symptoms and are used for mild withdrawal or to reduce the 
requirement for substitution opioids.
Substitution detoxification options available in South Africa:
•    Full agonist: Methadone9 (only available as Physeptone 
syrup (2 mg/5 ml) in South Africa; opioid detoxification 
is an off-label use); other – including codeine, morphine-
SR, and the atypical opioid, tramadol (none of these 
medications are registered for detoxification, nor are they 
widely researched or accepted as medication of choice for 
detoxification). 
•    Partial agonist: Buprenorphine.10
Non-substitution detoxification 
•    Alpha-2-agonist, e.g. clonidine.11
•    Symptomatic medications, including antidiarrhoea drugs, 
anti-emetics (nausea and vomiting), hyoscine butylbromide 
(abdominal cramps), non-steroidal anti-inflammatory 
drugs (muscle aches), paracetamol (headaches), antacid 
(indigestion), sedative-hypnotics or hydroxyzine (insomnia) 
or benzodiazepines (cramps, irritability, dysphoria, anxiety). 
(Use benzodiazepines with great care because of the risk of 
overdose with opioids and partial opioid agonists and the 
risk of co-morbid abuse and dependence.) Non-medications 
like hot/cold packs, relaxation, baths, massages, rubbing 
ointments, music, acupuncture, aromatherapy, etc. may also 
be used. 
Outpatient detoxification should be considered only in 
selected cases where it is considered safe to do so (risk of 
overdose and death). An infrastructure for daily supervised 
consumption of substitution opioids, regular follow-up and 
monitoring via random drug testing is required. Methadone 
should be used with great caution in outpatients, because of 
the risk of accidental overdoses; buprenorphine may be a safer 
option. 
Inpatient detoxification is safer, especially with high levels 
of opioid tolerance, poly-drug use, other co-morbidities and 
in pregnancy. (Long-term supervised care is important during 
pregnancy and substitute prescribing may be appropriate.) 
Patients should be educated that their level of tolerance is 
reduced during detoxification. The dose of illicit opioid that 
was used prior to detoxification may subsequently cause 
overdose.
Relapse prevention
A programme, including psychosocial rehabilitation and 
pharmacological interventions, to prevent relapse back to 
opioids must be in place prior to embarking on detoxification.  
Psychosocial interventions provide individuals in recovery 
with the skills to maintain sobriety and include cognitive 
behavioural therapy, motivational enhancement therapy, 
spiritual 12-step programmes and addressing social needs, such 
as homelessness, unemployment and family reintegration. 
Limited pharmacological interventions are available. 
Naltrexone is an opioid antagonist blocking opioid receptors 
without producing an effect, making it difficult to get high. 
It has been used orally, as a depot monthly injection or as a 
longer-term implant formulation. Naltrexone is unfortunately 
no longer registered in South Africa, but can be prescribed with 
Medicines Control Council (MCC) approval per patient and 
then ordered from overseas, e.g. using an online pharmacy. 
Only doctors experienced in treating opioid disorders should 
prescribe naltrexone.
Opioid dependence is a chronic disorder and relapse is 
common. Relapse could be viewed as a learning and growth 
opportunity. Many clients find that engaging in an aftercare 
programme, for example a self-help support group like 
Narcotics Anonymous, provide them with a useful support 
structure and may reduce relapse.  
Substitute opioid prescribing
Some addicts are unable to give up their opioids, and 
interventions to reduce harm may be considered until they are 
able to achieve total abstinence. 
Given the chronic relapsing nature of opioid dependence 
and frequent poor results of rapid detoxification and relapse 
prevention, treatment to reduce drug-related harm has become 
an important intervention in many countries. Substitution 
prescription of opioids, though not widely used in South 
Africa, is well established internationally and is supported 
by a large body of research literature and clinical practice.12 
Cochrane reviews confirm that maintenance treatment with 
methadone13 and buprenorphine14 has proven effectiveness, 
provided that adequate dosages are prescribed and appropriate 
supervision is given. 
Substitution is suitable for addicts who want to stop illicit 
opioid use, but are unable to achieve abstinence from all 
opioids at that time. They receive a prescribed individualised 
dose of methadone or buprenorphine at suitable doses 
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to suppress withdrawal and craving, and in the case of 
buprenorphine, to block the ‘high’ if illicit opioids are used on 
top. This provides the opportunity to stabilise their lifestyle, 
develop insight and reduce harm from illicit drug use. 
Methadone maintenance treatment has been shown to 
reduce morbidity,15 including HIV risk,16 incarceration,17 
other substance use18 and mortality19 associated with heroin 
dependence, and improves treatment retention. Compared 
with detoxification and psychosocial interventions, methadone 
maintenance treatment has a better outcome20 and the same is 
true for buprenorphine.21
The only formulation of methadone available in South Africa 
is Physeptone syrup, at a concentration of 2 mg/5 ml. This 
alcohol-containing cough syrup has a high sugar content and 
high viscosity, making accurate dispensing difficult. Users have 
to consume large volumes of the diluted formulation syrup (v. 
the 5 mg/5 ml formulation available abroad). Methadone is not 
currently registered for the management of opioid dependence 
in South Africa (off-label use). Methadone has good oral 
bioavailability and its long half-life allows for daily oral dosing. 
Because of its full agonist action, methadone substitution 
could be associated with a risk of accidental overdose. Ideally, 
the sugar-free 5 mg/5 ml elixir (not currently available in 
South Africa) rather than the cough syrup should be used for 
substitution prescribing.
Buprenorphine is available as a sublingual 2 mg or 8 mg 
tablet and its long half-life allows for once-daily or alternate-
day supervised consumption. Because it is a partial agonist, 
with increasing dose the active effects plateau, making it 
safer and less likely to result in accidental overdose than 
full agonists. Individuals also report a ‘clearer head’ with 
buprenorphine, in contrast to the ‘mental clouding’ sometimes 
experienced with methadone. The choice of substitution drug 
rests with the prescribing physician. A higher level of tolerance, 
patient preference and contraindications to use buprenorphine 
may be indications for choosing methadone.
Patients should be carefully selected for substitution 
treatment. They must have a diagnosis of opioid dependence 
with evidence of physical dependence (tolerance, withdrawal). 
Ideally they should have had at least one failed attempt at 
standard detoxification and rehabilitation, be well motivated 
and give informed consent.
Concomitant medical or psychiatric problems increase 
the complexity of management and may increase the risk of 
overdose and death.  Other precautions include high-risk poly-
drug use, especially drugs that cause sedation such as alcohol 
or benzodiazepines, and individuals who are at risk of self-
harm.
Substitution prescription poses risks if unregulated, 
including the potential for unsafe or unethical practices by 
medical professionals, black-market diversion and ‘doctor 
hopping’. It is therefore important that accreditation, guidelines 
and proper legislation be put into place to ensure that doctors 
who do substitution prescribing are properly trained and 
regulated to ensure patient safety.  Only medical practitioners 
who have received training or have experience in substitution 
prescribing should provide this treatment. Important 
elements include regular monitoring of patients, random drug 
screening to pick up relapse to illicit opioids or other addictive 
substances, and ongoing psychosocial interventions.  
Diversion of medication to the black market remains a valid 
concern, and adequate supervision of patients with regard 
to opioid dispensing and consumption is essential. A patient 
register would help to prevent ‘doctor-hopping’. 
The ultimate aim of opioid substitution treatment is eventual 
dose reduction and abstinence when the individual is ready, 
and treatment goals should be reviewed every 3 - 6 months.  
Some argue that a small number of addicts require lifelong 
substitution therapy owing to a relative endogenous opioid 
deficiency. Better results are obtained when opioid substitution 
is continued for at least 1 year before attempts are made to 
reduce the dose.
Schering Plough sponsored the meetings of the working group and 
publication. The authors served as members of the Schering-Plough 
advisory board. 
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